Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Menopause: new therapies.

Susan R Davis1

  • 1The Jean Hailes Foundation, Research Unit, 173 Carinish Road, Clayton, VIC 3168, Australia. suedavis@jeanhailes.org.au

The Medical Journal of Australia
|June 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of, and factors associated with, urogenital pelvic floor disorders among women from a refugee-background: A cross-sectional study.

Maturitas·2026
Same author

Associations between testosterone and pre-androgens and sexual function; findings from the Australian Women's Midlife Years Study.

Fertility and sterility·2026
Same author

Symptom profiles in the late reproductive stage, earlier premenopause and early perimenopause in the absence of vasomotor symptoms: a cross-sectional study.

BMJ sexual & reproductive health·2026
Same author

By the First Session: Initial Evidence Regarding the Early Therapeutic Environment.

Psychotherapy and psychosomatics·2026
Same author

Food and Drug Administration, Menopause Hormone Therapies, and Black Box Warnings on Cardiovascular Disease: New Evidence or New Directions?

Circulation. Population health and outcomes·2026
Same author

Transdermal testosterone gel vs placebo in women with diminished ovarian reserve prior to in vitro fertilization: a randomized, clinical trial.

Nature communications·2026
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

New hormone therapies offer potential benefits for postmenopausal women, but their long-term safety and efficacy require further investigation. Research is ongoing to evaluate treatments like selective estrogen receptor modulators (SERMs) for symptom relief and bone health.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Menopause Research

Background:

  • Traditional postmenopausal hormone therapy presents an unfavorable risk-benefit profile.
  • Low-dose estrogen-progestin therapies show potential for improved risk-benefit but require validation.
  • Selective tissue-acting steroids like tibolone offer symptom relief and bone protection, yet lack extensive long-term safety data.

Purpose of the Study:

  • To review the evolving landscape of postmenopausal hormone therapy.
  • To assess the potential of novel therapeutic strategies, including selective estrogen receptor modulators (SERMs).
  • To highlight the need for comprehensive safety and efficacy data for emerging treatments.

Main Methods:

  • Literature review of current and emerging postmenopausal hormone therapies.

Related Experiment Videos

  • Analysis of risk-benefit profiles for various treatment modalities.
  • Evaluation of data on symptom management, bone protection, and cardiovascular effects.

    • Main Results:

    • Tibolone and SERMs like raloxifene demonstrate efficacy in alleviating menopausal symptoms and preventing bone loss.
    • Long-term safety data for tibolone are limited.
    • SERMs are being investigated for combined use with estradiol and their cardiovascular impact is under evaluation.

    Conclusions:

    • Emerging therapies like tibolone and SERMs present promising alternatives to traditional hormone therapy for postmenopausal women.
    • Further research is crucial to establish the long-term safety and cardiovascular effects of these novel agents.
    • Optimizing treatment strategies requires a careful balance of efficacy, safety, and patient-specific factors.